This product is ready....

Phosphagenics, along with a dozen or so other Aussie biotechs, is presenting at the Australian Life Science Investment Showcase which will be held in San Francisco next week. The one-day AusBiotech event aims to showcase Australian life sciences companies to potential partners and investors. Events include presentations, one-on-one meetings and networking activities.

The “Recent developments/highlights”section of POH’s corporate profile caught my eye

Phosphagenics is the first company in the world to deliver therapeutic levels of oxymorphone via a transdermal patch. In a phase 1 multiple dose trial completed in late 2013, the TPM®/Oxymorphone patch successfully delivered oxymorphone through the skin, with plasma levels equivalent to a wide dose range of the oral form of oxymorphone (Opana® ER). This product is moving into Phase 2 and is ready for partnering.

There it is, loud and clear. “Value-adding” studies may be ongoing and Phase 2 trials may be penciled in but there appears no doubt that both the patch and company are ready to sign a deal NOW.

http://www.ausbiotech.org/userfiles/file/ALSIS San Francisco 2014 Handbook.pdf

http://lifescientist.com.au/events/...ce-investment-showcase-san-francisco-2-14-212